RESULTS	Although there were 5 patients who needed cardioversion or ablation because of frequent episodes of PAF/PAFL ( 2 in 25 mg/BID , 1 in 50 mg/BID , and 2 in 100 mg/BID of flecainide ) , neither death nor ventricular proarrhythmic event was reported .\